查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087865

嗜酸性細胞癌治療市場：2026-2032年全球市場預測（依療法、給藥途徑、藥物類型、年齡層、診斷方法、最終用戶和分銷管道分類）

Hurthle Cell Carcinoma Treatment Market by Treatment Type, Route Of Administration, Drug Type, Age Group, Diagnosis Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Hürthle 細胞癌治療市場將成長至 123.4 億美元，複合年成長率為 6.46%。

主要市場統計數據
基準年 2025 79.6億美元
預計年份：2026年 82.8億美元
預測年份 2032 123.4億美元
複合年成長率 (%) 6.46%

雖然嗜酸性細胞癌的治療屬於分化型甲狀腺癌治療譜系的一部分，但這種罕見的嗜酸性細胞甲狀腺腫瘤可能比傳統的濾泡性甲狀腺癌更具侵襲性，因此需要特殊的治療策略。經過同儕審查的內分泌腫瘤學文獻一致說明嗜酸性細胞癌是一種罕見疾病，僅佔所有甲狀腺癌的個位數百分比。此外，部分患者血管侵犯、淋巴結轉移或遠端轉移的發生率較高，據報道，與許多乳頭狀甲狀腺癌相比，其放射性碘攝取率較低。

先進醫療服務的需求取決於早期診斷檢測、高解析度子宮頸超音波、專業的細胞病理學和分子檢測、內分泌外科手術、選擇性放射性碘治療、左甲狀腺素抑制促甲狀腺激素（TSH）的給藥、影像檢查後續觀察以及針對進行性、放射性碘抗藥性疾病的全身性治療。對於醫療保健專業人員、保險公司和生命科學領域的利益相關相關人員而言，機會主要集中在精準的風險分層、多學科診療路徑、公平獲取生物標記以及基於檢驗臨床證據的標靶治療。

治療方式的變革性改變。

治療嗜酸性細胞癌的方法正從統一的「手術優先」模式轉向基於腫瘤大小、包膜和血管侵犯、淋巴結轉移情況、轉移模式、患者年齡、合併症以及分子特徵的個人化治療。雖然對於高風險腫瘤，全甲狀腺切除術仍然是常用的治療方法，但對於根據指南評估和專科醫生的外科判斷精心挑選的低危險病例，切除術也可能適用。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過提高影像審查、病理支持、基因組分析、臨床試驗匹配和後續觀察的速度和一致性，對哈特爾細胞癌的治療產生了日益顯著的影響。 AI 驅動的超音波和放射學工具有助於識別可疑的甲狀腺結節和復發徵兆，而數位病理演算法則有助於識別嗜酸性細胞形態，並幫助量化需要專家確認的特徵。

按地區分類的主要發現

北美在引入哈斯勒細胞癌先進療法方面發揮著主導作用，這得益於其在內分泌外科手術、分子診斷、放射性碘治療設施、主導標靶治療、臨床試驗以及基於指南的多學科癌症診療方面的廣泛應用。在歐洲，甲狀腺癌的診療服務也較為普及，這得益於專業的甲狀腺癌中心、國家級衛生技術評估、罕見癌症合作計畫以及跨境研究網路，但醫保報銷時間和診斷可及性因國家而異。

關鍵群體特定見解

在東協地區，由於超音波的廣泛應用、私營部門對腫瘤學的投資、核醫學服務的提升以及區域轉診網路的建立，對嗜酸細胞癌治療的需求日益成長；然而，分子檢測和標靶治療的可及性仍然不均衡。海灣合作理事會（GCC）成員國正優先推進癌症診療現代化、國家級基因組學舉措、三級腫瘤診療能力建設以及國際臨床合作，以支持複雜甲狀腺癌和晚期內分泌腫瘤的診療。

主要國家的概況

美國仍然是赫特爾細胞癌治療的全球標竿市場，這得益於符合NCCN指南的藥物、廣泛的分子檢測、FDA批准的針對合格的進行性甲狀腺癌的標靶治療，以及完善的臨床試驗體系。在加拿大，重點在於基於指南的內分泌腫瘤學、公共保險報銷改革以及區域癌症機構之間的合作。同時，墨西哥的進展主要集中在主要大都會圈的癌症中心，影像學檢查和專科手術的普及程度不斷提高。巴西擁有拉丁美洲最發達的甲狀腺腫瘤學生態系統，這得益於主要城市的大學附屬醫院、內分泌外科專家以及核醫學技術的普及。

為行業領導者提供的實用建議

產業領導者應優先考慮哈斯勒細胞癌的整合臨床路徑，將內分泌科、內分泌外科、病理科、核子醫學科、放射科、腫瘤內科、遺傳學和倖存者護理等各科室連結起來。最有價值的投資應包括：檢驗的分子檢測、腫瘤委員會工作流程、轉診夥伴關係、病患導航、專家病理審查，以及基於實證醫學的放射性碘治療與後續觀察或全身性治療之間的選擇。

調查方法

本執行摘要基於系統性的研究方法，整合了權威的臨床指南、監管規定、經同行評審的甲狀腺癌文獻、腫瘤學會的最新資訊、醫療技術評估趨勢以及來自癌症研究所和內分泌相關組織的公開資訊。本研究途徑重點在於已確立的證據，包括哈斯勒細胞癌的生物學特徵、手術治療、對放射性碘的反應、後續觀察標準以及分化型甲狀腺癌的全身性治療應用。

結論

赫特爾細胞癌的治療正朝著更精準和循證的方向發展，其基礎是熟練的手術操作、選擇性地使用放射性碘、基於風險的後續觀察以及針對進行性或難治性疾病的靶向全身治療。由於該疾病罕見，碘親和性存在個體差異，且可能呈現侵襲性進展，因此準確的診斷、專業的病理診斷以及多學科協作決策至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：嗜酸性細胞癌治療市場：依治療類型分類

  • 外科手術
    • 切除術
      • 全甲狀腺切除術
      • 甲狀腺部分切除術
    • 淋巴結清除術
      • 中央頸部淋巴擴清術
      • 頸側頸部淋巴擴清術
  • 放射性碘療法
    • 消融療法
    • 輔助性治療
  • 體外放射治療
    • 強度調控放射治療
    • 立體定位放射治療
  • 化療
  • 免疫療法

第8章：嗜酸性細胞癌治療市場：依給藥途徑分類

  • 腸外
    • 靜脈
    • 皮下
  • 口服
    • 藥片
    • 膠囊

第9章：嗜酸性細胞癌治療市場：依藥物類型分類

  • 品牌藥品
  • 學名藥

第10章：嗜酸性細胞癌治療市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第11章：嗜酸性細胞癌治療市場：依診斷類型分類

  • 診斷影像
    • 超音波檢查
    • 電腦斷層掃描
    • MRI
  • 切片檢查
    • 細針穿刺切片檢查
    • 核心針穿刺切片
  • 分子檢測

第12章：嗜酸性細胞癌治療市場：依最終用戶分類

  • 門診手術中心
  • 癌症研究所
  • 醫院
    • 民眾
    • 私人的
  • 專科診所
    • 腫瘤診所
    • 內分泌診所

第13章：嗜酸性細胞癌治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：嗜酸性細胞癌治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：嗜酸性細胞癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：赫特爾細胞癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Molecular Targeting Technologies, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0355054AC4AC

The Hurthle Cell Carcinoma Treatment Market is projected to grow by USD 12.34 billion at a CAGR of 6.46% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.96 billion
Estimated Year [2026] USD 8.28 billion
Forecast Year [2032] USD 12.34 billion
CAGR (%) 6.46%

Hurthle cell carcinoma treatment sits within the differentiated thyroid cancer care continuum but requires a specialized strategy because this rare oncocytic thyroid tumor can behave more aggressively than conventional follicular thyroid carcinoma. Peer-reviewed endocrine oncology literature consistently describes Hurthle cell carcinoma as uncommon, representing a small single-digit share of thyroid cancers, with higher rates of vascular invasion, nodal or distant spread in selected patients, and lower radioiodine avidity than many papillary thyroid cancers.

Demand for advanced care is shaped by earlier diagnostic workups, high-resolution neck ultrasound, expert cytopathology, molecular testing, endocrine surgery, selective radioactive iodine use, TSH-suppressive levothyroxine, surveillance imaging, and systemic therapy for progressive radioactive iodine-refractory disease. For healthcare providers, payers, and life sciences stakeholders, the opportunity is concentrated in precision risk stratification, multidisciplinary care pathways, equitable biomarker access, and targeted therapies supported by validated clinical evidence.

Transformative Shifts in the Treatment Landscape

The Hurthle cell carcinoma treatment landscape is moving from uniform surgery-first management toward individualized care based on tumor size, capsular and vascular invasion, nodal status, metastatic pattern, patient age, comorbidity, and molecular profile. Total thyroidectomy remains common for higher-risk tumors, while lobectomy may be appropriate in carefully selected low-risk cases under guideline-based evaluation and expert surgical judgment.

A major shift is the selective use of radioactive iodine because Hurthle cell tumors may show limited iodine uptake compared with other differentiated thyroid cancers. In advanced disease, clinical attention is increasingly focused on radioactive iodine-refractory differentiated thyroid cancer therapies, including multikinase inhibitors and biomarker-directed agents for actionable alterations such as RET, NTRK, BRAF, or other clinically relevant genomic findings. This transition is strengthening the role of tumor boards, reference laboratories, real-world evidence, and coordinated survivorship programs.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing Hurthle cell carcinoma treatment by improving the speed and consistency of imaging review, pathology support, genomic interpretation, trial matching, and longitudinal surveillance. AI-enabled ultrasound and radiology tools can help flag suspicious thyroid nodules or recurrent disease, while digital pathology algorithms may support recognition of oncocytic morphology and quantify features that require expert confirmation.

The cumulative impact is operational as well as clinical: AI can reduce reporting variability, prioritize high-risk cases, identify eligible patients for targeted therapy trials, and support adherence to surveillance schedules. However, adoption must remain evidence-led, with external validation, bias testing, clinician oversight, cybersecurity controls, and compliance with privacy frameworks such as HIPAA and GDPR.

Key Regional Insights

North America leads adoption of advanced Hurthle cell carcinoma treatment through strong access to endocrine surgery, molecular diagnostics, radioactive iodine facilities, targeted therapies, clinical trials, and guideline-driven multidisciplinary oncology. Europe shows broad uptake through specialist thyroid cancer centers, national health technology assessments, rare cancer collaboration, and cross-border research networks, although reimbursement timelines and diagnostic access vary by country.

Asia-Pacific is expanding its thyroid cancer treatment capabilities as China, Japan, India, South Korea, and Australia scale high-resolution imaging, nuclear medicine capacity, precision oncology infrastructure, and specialist cancer services. Latin America is improving access in major urban centers, led by Brazil and Mexico, but cost, referral delays, and uneven molecular testing availability remain important barriers. The Middle East, particularly GCC health systems, is investing in oncology centers, genomic medicine, and medical tourism-linked specialty care, while Africa remains highly heterogeneous, with progress concentrated in tertiary hospitals and persistent constraints in pathology, nuclear medicine, referral systems, and specialty drug access.

Key Group Insights

Within ASEAN, demand for Hurthle cell carcinoma treatment is rising alongside greater ultrasound utilization, private-sector oncology investment, expanding nuclear medicine services, and regional referral networks, although access to molecular testing and targeted therapies remains uneven. GCC countries are prioritizing cancer care modernization, national genomic initiatives, tertiary oncology capacity, and international clinical partnerships that support complex thyroid cancer management and advanced endocrine oncology.

The European Union benefits from centralized regulatory pathways, rare cancer research collaboration, and structured reimbursement review, supporting evidence-based uptake of diagnostics and targeted therapies. BRICS markets combine large patient populations with varied access to nuclear medicine, expert surgery, and genomics, making affordability, workforce training, and capacity expansion central themes. G7 countries generally lead in clinical trial access, companion diagnostics, health technology assessment, and real-world evidence generation. NATO markets overlap substantially with high-income healthcare systems, where resilience of medical isotope supply, oncology logistics, data protection, and cybersecurity are increasingly strategic considerations for continuity of thyroid cancer care.

Key Country Insights

The United States remains a global reference market for Hurthle cell carcinoma treatment due to NCCN-aligned care, broad molecular testing, FDA-approved targeted therapy availability for eligible advanced thyroid cancers, and strong clinical trial infrastructure. Canada emphasizes guideline-based endocrine oncology, public reimbursement review, and regional cancer agency coordination, while Mexico's progress is concentrated in major metropolitan cancer centers with growing access to imaging and specialized surgery. Brazil has the most developed thyroid oncology ecosystem in Latin America, supported by academic hospitals, specialist endocrine surgery, and nuclear medicine access in leading cities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist endocrine surgery with public health system reimbursement and multidisciplinary thyroid cancer services, while Germany and France are particularly important for diagnostics, pathology expertise, and oncology innovation. Russia maintains advanced care in major urban centers but faces regional access variation in molecular testing and specialty oncology services. China is scaling precision oncology and hospital capacity, India is expanding private and public cancer care, Japan and South Korea lead in technology-enabled diagnostics and structured oncology pathways, and Australia benefits from high-quality cancer registries, specialist thyroid cancer services, and established clinical governance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated Hurthle cell carcinoma pathways that connect endocrinology, endocrine surgery, pathology, nuclear medicine, radiology, medical oncology, genetics, and survivorship care. The highest-value investments include validated molecular testing, tumor board workflows, referral partnerships, patient navigation, expert pathology review, and evidence-based selection of radioactive iodine versus surveillance or systemic therapy.

Life sciences and diagnostics stakeholders should build real-world evidence programs for radioactive iodine-refractory disease, support equitable biomarker testing, and align market access strategies with guideline-recognized endpoints such as progression-free survival, response rate, safety, durability of response, and quality of life. Providers should standardize surveillance protocols, strengthen shared decision-making, and use AI only where clinical validation, transparency, privacy protection, and workflow integration are proven.

Research Methodology

This executive summary is built on a structured research approach that integrates secondary review of authoritative clinical guidelines, regulatory labels, peer-reviewed thyroid cancer literature, oncology society updates, health technology assessment trends, and public information from cancer institutes and endocrine organizations. The analysis emphasizes established evidence on Hurthle cell carcinoma biology, surgical management, radioactive iodine responsiveness, surveillance standards, and systemic therapy use in differentiated thyroid cancer.

Insights are triangulated across clinical practice patterns, regional healthcare infrastructure, reimbursement environments, diagnostic availability, guideline adoption, and innovation indicators. The methodology prioritizes verifiable data, excludes unsupported market-size claims, and applies an executive synthesis framework to convert clinical and commercial signals into decision-ready intelligence.

Conclusion

Hurthle cell carcinoma treatment is entering a more precise and evidence-driven phase, anchored by expert surgery, selective radioactive iodine use, risk-adapted surveillance, and targeted systemic therapy for advanced or refractory disease. The disease's rarity, variable iodine avidity, and potential for aggressive behavior make accurate diagnosis, expert pathology, and multidisciplinary decision-making essential.

Future competitiveness will depend on biomarker access, AI-enabled workflow efficiency, real-world evidence, referral network strength, and regional capacity building. Organizations that combine clinical rigor with scalable diagnostics, equitable access, validated digital tools, and patient-centered care pathways will be best positioned to improve outcomes in this specialized thyroid cancer treatment landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hurthle Cell Carcinoma Treatment Market, by Treatment Type

  • 7.1. Surgery
    • 7.1.1. Thyroidectomy
      • 7.1.1.1. Total Thyroidectomy
      • 7.1.1.2. Partial Thyroidectomy
    • 7.1.2. Lymph Node Dissection
      • 7.1.2.1. Central Neck Dissection
      • 7.1.2.2. Lateral Neck Dissection
  • 7.2. Radioactive Iodine Therapy
    • 7.2.1. Ablation Therapy
    • 7.2.2. Adjuvant Therapy
  • 7.3. External Beam Radiation Therapy
    • 7.3.1. Intensity-Modulated Radiation Therapy
    • 7.3.2. Stereotactic Body Radiation Therapy
  • 7.4. Chemotherapy
  • 7.5. Immunotherapy Therapy

8. Hurthle Cell Carcinoma Treatment Market, by Route Of Administration

  • 8.1. Parenteral
    • 8.1.1. Intravenous
    • 8.1.2. Subcutaneous
  • 8.2. Oral
    • 8.2.1. Tablets
    • 8.2.2. Capsules

9. Hurthle Cell Carcinoma Treatment Market, by Drug Type

  • 9.1. Branded Drugs
  • 9.2. Generic Drugs

10. Hurthle Cell Carcinoma Treatment Market, by Age Group

  • 10.1. Pediatric
  • 10.2. Adult
  • 10.3. Geriatric

11. Hurthle Cell Carcinoma Treatment Market, by Diagnosis Type

  • 11.1. Imaging
    • 11.1.1. Ultrasound
    • 11.1.2. CT Scan
    • 11.1.3. MRI
  • 11.2. Biopsy
    • 11.2.1. Fine Needle Aspiration
    • 11.2.2. Core Needle Biopsy
  • 11.3. Molecular Testing

12. Hurthle Cell Carcinoma Treatment Market, by End User

  • 12.1. Ambulatory Surgery Center
  • 12.2. Cancer Institute
  • 12.3. Hospital
    • 12.3.1. Public
    • 12.3.2. Private
  • 12.4. Specialty Clinic
    • 12.4.1. Oncology Clinics
    • 12.4.2. Endocrinology Clinics

13. Hurthle Cell Carcinoma Treatment Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Hurthle Cell Carcinoma Treatment Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Hurthle Cell Carcinoma Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Hurthle Cell Carcinoma Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Amgen Inc.
  • 18.3. AstraZeneca PLC
  • 18.4. Bayer AG
  • 18.5. BeiGene, Ltd.
  • 18.6. Blueprint Medicines Corporation
  • 18.7. Bristol-Myers Squibb Company
  • 18.8. Daiichi Sankyo Company, Limited
  • 18.9. Eisai Co., Ltd.
  • 18.10. Eli Lilly and Company
  • 18.11. Exelixis, Inc.
  • 18.12. F. Hoffmann-La Roche Ltd
  • 18.13. Gilead Sciences, Inc.
  • 18.14. GlaxoSmithKline plc
  • 18.15. Incyte Corporation
  • 18.16. Johnson & Johnson Services, Inc
  • 18.17. Merck & Co., Inc.
  • 18.18. Molecular Targeting Technologies, Inc.
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Regeneron Pharmaceuticals, Inc.
  • 18.22. Sun Pharmaceutical Industries Ltd.
  • 18.23. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THYROIDECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THYROIDECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THYROIDECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TOTAL THYROIDECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TOTAL THYROIDECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TOTAL THYROIDECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PARTIAL THYROIDECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PARTIAL THYROIDECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PARTIAL THYROIDECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LYMPH NODE DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LYMPH NODE DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LYMPH NODE DISSECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NECK DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NECK DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NECK DISSECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LATERAL NECK DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LATERAL NECK DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LATERAL NECK DISSECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIOACTIVE IODINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOACTIVE IODINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIOACTIVE IODINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ABLATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ABLATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ABLATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADJUVANT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADJUVANT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADJUVANT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTENSITY-MODULATED RADIATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTENSITY-MODULATED RADIATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTENSITY-MODULATED RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STEREOTACTIC BODY RADIATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STEREOTACTIC BODY RADIATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STEREOTACTIC BODY RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOTHERAPY THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOTHERAPY THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOTHERAPY THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRANDED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRANDED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRANDED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CT SCAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CT SCAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CT SCAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MRI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MRI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MOLECULAR TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MOLECULAR TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MOLECULAR TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AMBULATORY SURGERY CENTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AMBULATORY SURGERY CENTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AMBULATORY SURGERY CENTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER INSTITUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER INSTITUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER INSTITUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOCRINOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ENDOCRINOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENDOCRINOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 283. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 284. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 288. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 289. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 293. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 294. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 296. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 297. GCC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY THYROIDECTOMY, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY LYMPH NODE DISSECTION, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 335. BRICS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 336. G7 HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. G7 HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE